Skip to content

Relationship between blood magnesium level and vascular calcification and cardiovascular events in diabetic kidney disease

Relationship between blood magnesium level and vascular calcification and cardiovascular events in diabetic kidney disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077077
Enrollment
Unknown
Registered
2023-10-27
Start date
2023-11-06
Completion date
Unknown
Last updated
2023-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetic kidney disease

Interventions

low serum magnesium:NA
normal serum magnesium:NA

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Age greater than 18 years old, regardless of gender; ? The clinical diagnosis of patients with DKD in accordance with KDOQI diabetes and CKD clinical practice guidelines (2012 version) excludes kidney diseases caused by other reasons; ? Within the past 3 months, renal function has been stable, with a glomerular filtration rate (eGFR) of 15-90ml/min/1.73m2 ? The expected lifespan is greater than 2 years; ? Sign the informed consent form and cooperate with the follow-up.

Exclusion criteria

Exclusion criteria: ? Acute kidney injury occurred within 3 months ? Abnormal liver function, with Alanine transaminase and/or glutamic oxalic Transaminase reaching 2 times or more of the upper limit of normal value; ? Patients with primary parathyroid dysfunction or other non renal causes leading to abnormal calcium and phosphorus metabolism; ? Those who have suffered from unstable angina pectoris or cardiac insufficiency of Grade III-IV (NYHA grade) within 6 months, or active cerebral hemorrhage, or new cerebral infarction and other cerebrovascular diseases, or who need long-term Diuretic treatment for any reason; ? Have serious heart, lung, Central nervous system disease diseases or malignant tumors; ? Pregnant women, women preparing for pregnancy or lactation ? Individuals who have participated in any drug trial within the three months prior to being selected ? Those who cannot sign an informed consent form and do not agree to regular follow-up ? Other researchers believe that it is not suitable for inclusion in this trial

Design outcomes

Primary

MeasureTime frame
coronary CT;serum magnesium;ankle brachial index;pulse wave conduction velocity (PWV);

Countries

China

Contacts

Public ContactLing Qin

Shanghai Tenth People's Hospital

coffee1170330@126.com+86 189 1768 4066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026